US4866034A
(en)
*
|
1982-05-26 |
1989-09-12 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
CA1225592A
(fr)
*
|
1983-08-26 |
1987-08-18 |
Ribi Immunochem Research Inc. |
Endotoxine detoxifiee raffinee
|
US4987237A
(en)
*
|
1983-08-26 |
1991-01-22 |
Ribi Immunochem Research, Inc. |
Derivatives of monophosphoryl lipid A
|
US4663306A
(en)
*
|
1983-09-23 |
1987-05-05 |
Ribi Immunochem Research, Inc. |
Pyridine-soluble extract-refined detoxified endotoxin composition and use
|
JPS61151157A
(ja)
*
|
1984-12-25 |
1986-07-09 |
Seiko Instr & Electronics Ltd |
タンパク質を加水分解する方法
|
US4877611A
(en)
*
|
1986-04-15 |
1989-10-31 |
Ribi Immunochem Research Inc. |
Vaccine containing tumor antigens and adjuvants
|
US4806352A
(en)
*
|
1986-04-15 |
1989-02-21 |
Ribi Immunochem Research Inc. |
Immunological lipid emulsion adjuvant
|
US4929604A
(en)
*
|
1986-05-28 |
1990-05-29 |
Board Of Regents, The University Of Texas System |
Lipopolysaccharides of reduced toxicity and the production thereof
|
US4845036A
(en)
*
|
1987-02-03 |
1989-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for isolation of the B oligomer of pertussis toxin
|
JPH01141942U
(fr)
*
|
1988-03-24 |
1989-09-28 |
|
|
JPH01180041U
(fr)
*
|
1988-06-09 |
1989-12-25 |
|
|
US4950645A
(en)
*
|
1988-07-08 |
1990-08-21 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
US5416070A
(en)
*
|
1988-07-08 |
1995-05-16 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
JPH04501663A
(ja)
*
|
1988-09-23 |
1992-03-26 |
ユニバーシティ・オブ・サザン・カリフォルニア |
黒色腫用免疫療法ワクチン
|
JPH02124341U
(fr)
*
|
1989-03-24 |
1990-10-12 |
|
|
US5286718A
(en)
*
|
1991-12-31 |
1994-02-15 |
Ribi Immunochem Research, Inc. |
Method and composition for ameliorating tissue damage due to ischemia and reperfusion
|
US6218166B1
(en)
|
1994-12-09 |
2001-04-17 |
John Wayne Cancer Institute |
Adjuvant incorporation into antigen carrying cells: compositions and methods
|
US6190657B1
(en)
*
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US5762943A
(en)
*
|
1996-05-14 |
1998-06-09 |
Ribi Immunochem Research, Inc. |
Methods of treating type I hypersensitivity using monophosphoryl lipid A
|
US6491919B2
(en)
*
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
IL134936A0
(en)
|
1997-09-10 |
2001-05-20 |
Vion Pharmaceuticals Inc |
Genetically modified tumor-targeted bacteria with reduced virulence
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
WO1999056776A2
(fr)
*
|
1998-05-07 |
1999-11-11 |
Corixa Corporation |
Composition d'adjuvant et procedes d'utilisation de celle-ci
|
US6375952B1
(en)
|
1998-08-07 |
2002-04-23 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US6013640A
(en)
|
1998-08-21 |
2000-01-11 |
Ribi Immunochem Research, Inc. |
Phosphoglycolipid and methods for its use
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
JP2002531129A
(ja)
|
1998-12-08 |
2002-09-24 |
コリクサ コーポレイション |
クラミジア感染の処置および診断のための化合物および方法
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US6566500B1
(en)
|
1999-03-30 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinaceous compounds
|
CZ20013527A3
(cs)
|
1999-04-02 |
2002-10-16 |
Corixa Corporation |
Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
AU764969B2
(en)
|
1999-04-19 |
2003-09-04 |
Smithkline Beecham Biologicals (Sa) |
Vaccines
|
US20020022032A1
(en)
*
|
1999-04-23 |
2002-02-21 |
Curry Patrick Mark |
Immuno-adjuvant PDT treatment of metastatic tumors
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
US6962696B1
(en)
*
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
EP1229931A4
(fr)
*
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
Proteines hybrides de mycobacterium tuberculosis
|
EP1964573B1
(fr)
|
1999-10-22 |
2014-11-26 |
Aventis Pasteur Limited |
Procédé d'induction et/ou amélioration d'une réponse immune vers des antigènes de tumeurs
|
GB0000891D0
(en)
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6699846B2
(en)
|
2000-03-17 |
2004-03-02 |
Corixa Corporation |
Mono- and disaccharides for the treatment of nitric oxide related disorders
|
WO2001081379A2
(fr)
|
2000-04-21 |
2001-11-01 |
Corixa Corporation |
Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
|
US7851212B2
(en)
|
2000-05-10 |
2010-12-14 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
|
DK1284740T3
(da)
|
2000-05-19 |
2008-08-04 |
Corixa Corp |
Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
|
US20030139356A1
(en)
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
PT2133100E
(pt)
*
|
2000-06-20 |
2012-01-11 |
Corixa Corp |
Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
PT2266603E
(pt)
|
2000-10-18 |
2012-11-02 |
Glaxosmithkline Biolog Sa |
Vacinas tumorais
|
WO2002074336A2
(fr)
|
2001-02-23 |
2002-09-26 |
Glaxosmithkline Biologicals S.A. |
Vaccin
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
US20030031684A1
(en)
*
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
TWI228420B
(en)
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
US20030108565A1
(en)
|
2001-07-10 |
2003-06-12 |
Johnson Mark E. |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
EP1427826B1
(fr)
*
|
2001-09-20 |
2011-04-20 |
Glaxo Group Limited |
Vaccins VIH-RT-nef-Gag à DNA avec codons optimisés
|
CA2860702C
(fr)
|
2001-12-17 |
2019-02-26 |
Corixa Corporation |
Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
|
WO2003070187A2
(fr)
*
|
2002-02-15 |
2003-08-28 |
Corixa Corporation |
Proteines de fusion de mycobacterium tuberculosis
|
AU2003213640A1
(en)
*
|
2002-02-28 |
2003-09-16 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
MXPA05000407A
(es)
|
2002-07-08 |
2005-04-19 |
Corixa Corp |
Procedimientos para la produccion de fosfato de aminoalquilglucosaminida e inmunoefectores de disacarido, e intermediarios para los mismos.
|
CA2491310C
(fr)
|
2002-07-15 |
2015-10-06 |
Board Of Regents, The University Of Texas System |
Compositions comprenant des derives de la duramycine impermeants vis-a-vis des parois cellulaires
|
ATE414176T1
(de)
|
2002-07-18 |
2008-11-15 |
Univ Washington |
Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
|
NZ539509A
(en)
|
2002-10-23 |
2008-05-30 |
Glaxosmithkline Biolog Sa |
Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2544850C2
(ru)
|
2003-01-06 |
2015-03-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
BRPI0414073A
(pt)
|
2003-09-02 |
2006-10-24 |
Glaxosmithkline Biolog Sa |
método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
|
EP2816351A3
(fr)
*
|
2004-01-27 |
2015-03-25 |
Compugen Ltd. |
Procédés et systèmes d'annotation de séquences biomoléculaires
|
US8409590B2
(en)
*
|
2004-02-11 |
2013-04-02 |
Ligocyte Pharmaceuticals, Inc. |
Anthrax antigens and methods of use
|
EP2497831B1
(fr)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
Vaccin contre la Tuberculosis utilisant des vecteurs de vaccin à base de HCMV
|
CA2565500A1
(fr)
|
2004-05-28 |
2005-12-15 |
Glaxosmithkline Biologicals S.A. |
Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US8846051B2
(en)
|
2004-10-08 |
2014-09-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by deoptimization of synonymous codons
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006100111A1
(fr)
*
|
2005-03-23 |
2006-09-28 |
Glaxosmithkline Biologicals S.A. |
Composition
|
JP2008534594A
(ja)
|
2005-03-31 |
2008-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
クラミジア感染に対するワクチン
|
CA2607715C
(fr)
|
2005-04-29 |
2015-11-24 |
Glaxosmithkline Biologicals S.A. |
Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US7622128B2
(en)
*
|
2005-12-13 |
2009-11-24 |
University Of Washington |
Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
EP1981905B1
(fr)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vaccin contre chlamydia
|
WO2008094183A2
(fr)
*
|
2006-07-11 |
2008-08-07 |
University Of Connecticut |
Utilisation de souches de plasmodium conditionnelles exemptes de transporteurs de nutriments dans la vaccination anti-paludique
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
EP2043682B1
(fr)
|
2006-07-17 |
2014-04-02 |
GlaxoSmithKline Biologicals S.A. |
Vaccin anti-grippal
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
PT2486938T
(pt)
|
2006-09-26 |
2018-06-12 |
Infectious Disease Res Inst |
Composição para vacina contendo adjuvante sintético
|
WO2008059307A2
(fr)
*
|
2006-11-16 |
2008-05-22 |
Om Pharma |
Bêta 1,6 glucosamine disaccharides fonctionnalisés et leur procédé de préparation
|
DK2136836T3
(en)
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
EP3539567A1
(fr)
|
2007-07-02 |
2019-09-18 |
Etubics Corporation |
Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
|
BRPI0815008B8
(pt)
*
|
2007-08-02 |
2021-05-25 |
Biondvax Pharmaceuticals Ltd |
vacinas multiméricas com múltiplos epítopos contra influenza
|
KR20100068390A
(ko)
|
2007-08-13 |
2010-06-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
US20090215908A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Toll like receptor (tlr) signaling antagonist
|
EP2570137A3
(fr)
|
2007-11-07 |
2013-08-21 |
Celldex Therapeutics, Inc. |
Anticorps qui se lient à la cellule dendritique et épithéliale 205 (DEC-205)
|
CA2744739A1
(fr)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Antigenes de chlamydia
|
EP3109258B1
(fr)
*
|
2007-12-24 |
2019-01-23 |
ID Biomedical Corporation of Quebec |
Antigènes recombinants du rsv
|
US20110052501A1
(en)
*
|
2008-01-31 |
2011-03-03 |
Liat Dassa |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
US8877208B2
(en)
|
2008-05-23 |
2014-11-04 |
The Regents Of The University Of Michigan |
Multivalent nanoemulsion vaccines
|
BRPI0914224A2
(pt)
|
2008-06-19 |
2019-09-24 |
Variation Biotechnologies Inc |
composições e métodos para tratar a gripe
|
AU2009270399A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Id Biomedical Corporation Of Quebec |
Chimeric respiratory syncytial virus polypeptide antigens
|
EP2349209A2
(fr)
|
2008-09-26 |
2011-08-03 |
Nanobio Corporation |
Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
|
KR20110091560A
(ko)
|
2008-12-03 |
2011-08-11 |
프로테아 벡신 테크놀로지스 엘티디. |
글루타밀 tRNA 합성효소(GtS) 단편들
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
EP2398821B1
(fr)
|
2009-02-17 |
2017-08-30 |
GlaxoSmithKline Biologicals S.A. |
Vaccin à virus inactivé contre la dengue, contenant un adjuvant sans aluminium
|
US20110097418A1
(en)
*
|
2009-05-29 |
2011-04-28 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
TWI494125B
(zh)
|
2009-06-05 |
2015-08-01 |
Infectious Disease Res Inst |
合成的葡萄吡喃糖基脂質佐劑
|
EP3020412B1
(fr)
|
2009-06-16 |
2017-10-11 |
The Regents of the University of Michigan |
Vaccins en nanoémulsion
|
EA201270062A1
(ru)
|
2009-06-24 |
2013-02-28 |
АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК |
Вакцина
|
DK2445526T3
(en)
|
2009-06-24 |
2016-06-27 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV antigens.
|
CA2767392C
(fr)
|
2009-07-06 |
2017-03-14 |
Variation Biotechnologies, Inc. |
Procedes de preparation de vesicules et formulations obtenues a partir de celles-ci
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
US20120164176A1
(en)
|
2009-07-15 |
2012-06-28 |
Kurt Swanson |
Rsv f protein compositions amd methods for making same
|
ES2538007T3
(es)
|
2009-09-16 |
2015-06-16 |
Vaxart, Inc. |
Estrategia de inmunización para prevenir una infección por H1N1
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
WO2011067758A2
(fr)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
WO2011130434A2
(fr)
|
2010-04-13 |
2011-10-20 |
Celldex Therapeutics Inc. |
Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
CA2840079C
(fr)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions et methodes pour traiter la grippe
|
WO2012041669A1
(fr)
|
2010-09-27 |
2012-04-05 |
Crucell Holland B.V. |
Régime de vaccination de type amorce rappel hétérologue contre la malaria
|
CN103237560B
(zh)
|
2010-10-15 |
2016-05-11 |
葛兰素史密丝克莱恩生物有限公司 |
巨细胞病毒gb抗原
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
PT3023106T
(pt)
|
2010-12-14 |
2019-11-04 |
Glaxosmithkline Biologicals Sa |
Composição antigénica de micobactéria
|
MX359103B
(es)
|
2011-01-13 |
2018-09-14 |
Variation Biotechnologies Inc |
Composiciones y sus usos en el tratamiento de infecciones virales.
|
US20130323280A1
(en)
|
2011-01-13 |
2013-12-05 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
AU2011360572B2
(en)
|
2011-02-22 |
2017-03-02 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
JP2014527398A
(ja)
|
2011-06-21 |
2014-10-16 |
オンコファクター コーポレイション |
がんの療法および診断のための組成物および方法
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PL2758432T3
(pl)
|
2011-09-16 |
2019-08-30 |
Ucb Biopharma Sprl |
Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2013104995A2
(fr)
|
2012-01-12 |
2013-07-18 |
Variation Biotechnologies, Inc. |
Compositions et méthodes de traitement d'infections virales
|
WO2013111012A2
(fr)
|
2012-01-27 |
2013-08-01 |
Variation Biotechnologies, Inc. |
Procédés et compositions pour agents thérapeutiques
|
PL2811981T3
(pl)
|
2012-02-07 |
2019-09-30 |
Infectious Disease Research Institute |
Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
|
JP2015514696A
(ja)
|
2012-03-18 |
2015-05-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ヒト・パピローマウイルスに対するワクチン接種方法
|
EP2833900B1
(fr)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
|
EP2666785A1
(fr)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Vaccins basés sur la protéine complément C5a
|
RU2659149C2
(ru)
|
2012-08-03 |
2018-06-28 |
Инфекшес Дизиз Рисерч Инститьют |
Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
AU2013301312A1
(en)
|
2012-08-06 |
2015-03-19 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against RSV and B. pertussis
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(fr)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
Vaccin à base de PCSK9
|
US10232035B2
(en)
|
2012-09-14 |
2019-03-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes virus and use thereof in vaccines
|
SI2928489T1
(sl)
|
2012-12-05 |
2019-05-31 |
Glaxosmithkline Biologicals S.A. |
Imunogeni sestavek
|
TWI664976B
(zh)
|
2013-01-02 |
2019-07-11 |
美商迪科生物系統公司 |
使用細菌治療癌症之組成物和方法
|
ES2959258T3
(es)
|
2013-02-07 |
2024-02-22 |
Childrens Medical Center |
Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
UY35418A
(es)
|
2013-03-15 |
2014-10-31 |
Glaxosmithkline Biolog Sa |
Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
US9919029B2
(en)
|
2013-07-26 |
2018-03-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
AU2014304545A1
(en)
|
2013-08-05 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
KR102399854B1
(ko)
|
2013-09-19 |
2022-05-19 |
노바백스, 인코포레이티드 |
면역원성 중동호흡기증후군 코로나바이러스 (ΜERS-CoV) 조성물 및 방법
|
JP6306700B2
(ja)
|
2013-11-01 |
2018-04-04 |
ユニバーシティ オブ オスロUniversity of Oslo |
アルブミン改変体及びその使用
|
WO2015071763A2
(fr)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
|
WO2015092710A1
(fr)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Administration simultanée controlatérale de vaccins
|
PT3089754T
(pt)
|
2013-12-31 |
2021-07-23 |
Infectious Disease Res Inst |
Formulações de vacina de dose única
|
EP3107568B1
(fr)
|
2014-02-20 |
2024-03-27 |
Vaxart, Inc. |
Formulations pour administration dans l'intestin grêle
|
CA2944768C
(fr)
|
2014-04-03 |
2022-08-30 |
Biondvax Pharmaceuticals Ltd. |
Compositions de polypeptides multimeres-multi-epitopes de grippe et leur production
|
WO2015179270A2
(fr)
|
2014-05-19 |
2015-11-26 |
Board Of Regents, The University Of Texas System |
Plate-forme combinatoire pour la présentation d'adjuvants et d'antigènes de surface
|
WO2015189425A1
(fr)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Combinaisons immunogènes
|
PL3160500T3
(pl)
|
2014-06-25 |
2020-02-28 |
Glaxosmithkline Biologicals S.A. |
Immunogenna kompozycja clostridium difficile
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
EP4112076A1
(fr)
|
2014-10-10 |
2023-01-04 |
The Regents of The University of Michigan |
Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
|
JP6738348B2
(ja)
|
2014-12-19 |
2020-08-12 |
リジェネサンス ベスローテン フェンノートシャップ |
ヒトc6に結合する抗体およびその使用
|
JP6647315B2
(ja)
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
EP4226937A3
(fr)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Virus non neuro-invasifs et leurs utilisations
|
EP3268037B1
(fr)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Agonistes cd27
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
WO2016180852A1
(fr)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés de préparation de cellules t spécifiques de l'antigène à partir d'un échantillon de sang de cordon ombilical
|
CA2986961C
(fr)
|
2015-05-26 |
2023-07-25 |
Ohio State Innovation Foundation |
Strategie vaccinale a base de nanoparticules contre le virus de la grippe porcine
|
US11433146B2
(en)
|
2015-06-12 |
2022-09-06 |
Vaxart, Inc. |
Formulations for small intestinal delivery of RSV and norovirus antigens
|
WO2017062246A1
(fr)
|
2015-10-05 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Souche de rotavirus humain g9p[6] et utilisation comme vaccin
|
US11376324B2
(en)
|
2016-03-02 |
2022-07-05 |
The Board Of Regents Of The University Of Texas System |
Sting activating nanovaccine for immunotherapy
|
WO2017158421A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines anti-virales synthétiques
|
EP3430039A1
(fr)
|
2016-03-14 |
2019-01-23 |
Universitetet I Oslo |
Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
|
CN109071665B
(zh)
|
2016-04-18 |
2022-11-01 |
塞德斯医疗公司 |
结合人cd40的激动性抗体及其用途
|
US11344619B2
(en)
|
2016-05-16 |
2022-05-31 |
Access To Advanced Health Institute |
Formulation containing TLR agonist and methods of use
|
CA3023672A1
(fr)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Liposomes pegyles et procedes d'utilisation
|
WO2017205225A2
(fr)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions et méthodes de traitement de la tuberculose secondaire et des infections à mycobacterium non tuberculeuses
|
MX2018014602A
(es)
|
2016-05-27 |
2019-06-10 |
Etubics Corp |
Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
|
AU2017273650B2
(en)
|
2016-06-01 |
2022-08-18 |
Access To Advanced Health Institute |
Nanoalum particles containing a sizing agent
|
EP3471761A2
(fr)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Fragments de vaccin de liaison à hla et leurs utilisations
|
JP7146732B2
(ja)
|
2016-07-13 |
2022-10-04 |
オハイオ ステート イノベーション ファウンデーション |
宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
|
EP3504230A1
(fr)
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Peptides de fusion avec des antigènes liés à des fragments courts de chaîne invariante (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
MX2019003035A
(es)
|
2016-09-16 |
2019-09-13 |
Infectious Disease Res Inst |
Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
|
WO2018060288A1
(fr)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions et méthodes de traitement d'une infection par hpv persistante
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
WO2018096396A1
(fr)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Variants d'albumine et leurs utilisations
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
CN110035770B
(zh)
|
2016-12-07 |
2023-06-16 |
葛兰素史密丝克莱恩生物有限公司 |
新方法
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
CA3043790A1
(fr)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Nouvelles proteines f du vrs de pre-fusion recombinant et leurs utilisations
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
CN110945022B
(zh)
|
2017-04-19 |
2024-04-05 |
生物医学研究所 |
作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
|
EP3615061A1
(fr)
|
2017-04-28 |
2020-03-04 |
GlaxoSmithKline Biologicals S.A. |
Vaccination
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
IE87413B1
(en)
|
2017-05-30 |
2023-07-19 |
Glaxosmithkline Biologicals Sa |
Novel methods for manufacturing an adjuvant
|
MX2019015076A
(es)
|
2017-06-15 |
2020-08-03 |
Infectious Disease Res Inst |
Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
|
CA3066020A1
(fr)
|
2017-06-16 |
2018-12-20 |
Glaxosmithkline Biologicals Sa |
Methode de traitement
|
WO2019035963A1
(fr)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
Compositions à nanoparticules pour vaccins contre les salmonelles
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
CA3078223A1
(fr)
|
2017-09-08 |
2019-03-14 |
Infectious Disease Research Institute |
Formulations liposomales comprenant de la saponine et procedes d'utilisation
|
MX2020005481A
(es)
|
2017-12-01 |
2020-12-07 |
Glaxosmithkline Biologicals Sa |
Purificacion de saponina.
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
US20210046177A1
(en)
|
2018-01-26 |
2021-02-18 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
TW201946650A
(zh)
|
2018-03-12 |
2019-12-16 |
美商詹森藥物公司 |
針對腹內感染之疫苗
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
WO2019239311A1
(fr)
|
2018-06-12 |
2019-12-19 |
Glaxosmithkline Biologicals Sa |
Polynucléotides et polypeptides d'adénovirus
|
EP3581201A1
(fr)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 polypeptides et leurs utilisations
|
US20210292395A1
(en)
|
2018-07-31 |
2021-09-23 |
Glaxosmithkline Biologicals Sa |
Antigen purification method
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
EP3897846A1
(fr)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Méthodes d'induction d'une réponse immunitaire
|
CN113573730A
(zh)
|
2019-03-05 |
2021-10-29 |
葛兰素史密斯克莱生物公司 |
乙型肝炎免疫方案和组合物
|
MX2021014363A
(es)
|
2019-05-25 |
2022-02-21 |
Infectious Disease Res Inst |
Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
|
JP2022535091A
(ja)
|
2019-06-05 |
2022-08-04 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
サポニン精製
|
US20220273789A1
(en)
|
2019-07-21 |
2022-09-01 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
US20230201334A1
(en)
|
2019-07-24 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
EP3777884A1
(fr)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
US20210069321A1
(en)
|
2019-09-09 |
2021-03-11 |
Glaxosmithkline Biologicals Sa |
Immunotherapeutic compositions
|
US20220362368A1
(en)
|
2019-10-02 |
2022-11-17 |
Janssen Vaccines & Prevention B.V. |
Staphylococcus peptides and methods of use
|
EP4058581A1
(fr)
|
2019-11-15 |
2022-09-21 |
Infectious Disease Research Institute |
Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
|
WO2021122551A1
(fr)
|
2019-12-19 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Antigènes de s. aureus et compositions associées
|
JP7485771B2
(ja)
|
2020-01-16 |
2024-05-16 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
FimH変異体、その組成物、及びその使用
|
US11376320B2
(en)
|
2020-03-05 |
2022-07-05 |
Iowa State University Research Foundation, Inc. |
Immunogenic and vaccine compositions against SARS-CoV-2
|
JP2023524136A
(ja)
|
2020-05-05 |
2023-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
マイクロ流体混合デバイス及び使用方法
|
EP4158352A1
(fr)
|
2020-06-01 |
2023-04-05 |
Loop Diagnostics, S.L. |
Méthode et trousse de détection précoce de septicémie
|
WO2021245611A1
(fr)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Protéines modifiées de spicule de coronavirus bêta
|
WO2022029024A1
(fr)
|
2020-08-03 |
2022-02-10 |
Glaxosmithkline Biologicals Sa |
PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
|
CA3174411A1
(fr)
|
2020-09-04 |
2022-03-10 |
Ryan M. Kramer |
Arn co-lyophilise et support lipidique nanostructure
|
CA3202549A1
(fr)
|
2020-12-02 |
2022-06-09 |
Glaxosmithkline Biologicals Sa |
Nouveaux antigenes
|
WO2022122830A2
(fr)
|
2020-12-09 |
2022-06-16 |
Glaxosmithkline Biologicals Sa |
Saponines
|
WO2022136563A2
(fr)
|
2020-12-24 |
2022-06-30 |
Plant Bioscience Limited |
Procédés et compositions
|
AR124604A1
(es)
|
2021-01-12 |
2023-04-12 |
Janssen Pharmaceuticals Inc |
Mutantes de fimh, composiciones con los mismos y uso de los mismos
|
EP4032547A1
(fr)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Fragments dérivés du hsv 1 fce pour le traitement du hsv
|
CN117222428A
(zh)
|
2021-02-11 |
2023-12-12 |
葛兰素史克生物有限公司 |
Hpv疫苗生产
|
TW202304504A
(zh)
|
2021-04-01 |
2023-02-01 |
美商詹森藥物公司 |
大腸桿菌o18生物軛合物之生產
|
AU2022253269A1
(en)
|
2021-04-09 |
2023-11-23 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
WO2023020993A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023020994A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023020992A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023077521A1
(fr)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Constructions bispécifiques anti-ilt4 et anti-pd-1
|
WO2023144665A1
(fr)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Protéines de cytomégalovirus humain modifiées
|
WO2023180677A1
(fr)
|
2022-03-25 |
2023-09-28 |
Plant Bioscience Limited |
Biosynthèse
|
WO2023242187A1
(fr)
|
2022-06-15 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Modification enzymatique de saponines
|
GB202209588D0
(en)
|
2022-06-29 |
2022-08-10 |
Plant Bioscience Ltd |
Methods and compositions
|
WO2024052882A1
(fr)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Composition de vaccin immunogène incorporant une saponine
|
WO2024133160A1
(fr)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Compositions pour le traitement de l'hépatite b
|